REGULATORY

MOF Proposes Full Implementation of Cost-Effective Assessments as Precondition for Full-Scale Introduction of Premium for New Drug Development

November 2, 2015

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Ministry of Finance (MOF) presented a detailed proposal on the reform of the NHI pricing system at a subcommittee meeting of its Fiscal System Council on October 30. The MOF asked that if the council is considering the full-scale…

To read the full story

Fiscal System Council Approves MOF’s Proposal for NHI Pricing System Reform
November 2, 2015
MOF Asks Fiscal System Council to Issue Conclusion on Market Price Survey for FY2017 Revision “by Mid-2016 at Latest”
November 2, 2015

REGULATORY

Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
June 25, 2026
Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026
Japan Diet Begins Deliberations on Immunization Act Revision
June 25, 2026
US Opens Probe into German Drug Pricing Policies; Could Japan Be Next?
June 24, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry

By Philip Carrigan

Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…